Treatment.com AI has signed a letter of intent to acquire Alea Health, a UAE-based technology company specialising in AI for primary and mental healthcare.

This move is set to bolster Treatment's capabilities in the mental health and healthtech sectors, leveraging Alea's AI-driven online therapy platform.

Utilising conversational AI and voice technology, Alea Health's platform streamlines patient intake and follow-up, aiming to minimise administrative work and improve patient engagement.

This acquisition is in line with Treatment's vision to implement conversational AI across healthcare delivery within the next five to ten years, impacting areas such as patient intake, clinical decision support, and mental health therapy.

The integration of Alea Health's technology with the Global Library of Medicine (GLM) of Treatment is expected to deliver a comprehensive healthcare solution.

This acquisition marks Treatment's first significant investment in the Middle East, providing an opportunity to establish local partnerships and modernise healthcare in the region.

Alea Health's approach to mental health services incorporates AI, sentiment analysis, and natural language processing of voice data to improve therapeutic matching while predicting outcomes.

Alea Health co-founder and CEO Richard Dallala said: “By integrating our AI capabilities with the GLM library, we can extend the reach of our technology to a wider audience, creating the foundation for a deeper impact on healthcare outcomes.”

The Letter of Intent outlines that Treatment will acquire all issued and outstanding ordinary shares of Alea.

Treatment will make a cash payment of $15,000 within seven business days from the letter of intent execution, $180,000 to the holder of a simple agreement for future equity note of Alea Health on the proposed deal’s concluding date.

The company will also pay $120,000 on the closing date to the shareholders of Alea and issue common shares with a total deemed value of $100,000 on the closing date.